When Wegovy weight loss has stopped: how to think about what comes next

Is this a normal plateau, or a sign that something else is going on?

The human body does not give up weight in a straight line. Even on effective treatment, most people experience periods where the scales stop moving, sometimes for several weeks. During sustained weight loss, your body reduces its resting energy expenditure, it needs fewer calories to maintain itself at a lower weight. That gap between 'calories in' and 'calories burned' naturally narrows over time, and progress slows as a result. This is physiology, not failure.

What matters is working out which kind of plateau you are in. Some are temporary, caused by factors like a recent illness, a change in activity levels, stress, or being partway through a titration step. Others reflect a genuine metabolic adaptation that might warrant a clinical conversation about your dose or your wider approach. There is also a third possibility: you may have reached a stable weight that your body is defending, which happens to some people on any weight-loss treatment. The reasons weight loss stops on Wegovy vary considerably from person to person, and the distinction matters for deciding what comes next.

The worst thing to do is assume it is permanent and stop treatment abruptly. Abruptly stopping semaglutide is associated with weight returning, sometimes quickly. That is a decision to make with a clinician, not alone.

What Wegovy's clinical evidence tells us about plateaus

In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks. That weight loss was not linear, the rate of loss slowed substantially in the second half of the trial as participants approached a new stable weight. So a plateau in, say, month six or seven is not unusual even among people who go on to achieve meaningful overall results.

NICE's guidance on semaglutide (TA875) sets a clinically derived threshold: if less than 5% weight loss has occurred after six months at the maintenance dose, the guidance recommends reviewing whether it is appropriate to continue. That threshold exists precisely because Wegovy does not work identically for everyone, and the guidance from NICE's appraisal of semaglutide (TA875) helps prescribers make that call in a structured way. Crucially, the six-month clock runs from the maintenance dose, not from day one, many people spend the first months still working up through the titration schedule.

If you are still on an early dose and your weight has levelled off, the clinical question is whether the next titration step, reviewed by your prescriber, changes the picture. That is different from a plateau on the full maintenance dose.

Lifestyle factors that interact with the medicine

Wegovy reduces appetite and slows gastric emptying, but it works alongside diet and activity, not instead of them. One pattern prescribers recognise: as appetite falls and eating habits change, some people inadvertently reduce protein and fibre intake in favour of whatever seems easiest to manage. Over time, that can affect both the rate of weight loss and muscle retention, which in turn affects metabolism.

This is not a lecture on willpower. The NHS's guidance on semaglutide is clear that the medicine is intended alongside a reduced-calorie diet and increased physical activity, and those elements interact with what the medicine can achieve. If life circumstances have shifted (a new job, a change in routine, disrupted sleep) that context is worth sharing with your prescriber rather than treating as irrelevant.

The broader picture of how semaglutide works can help frame what the medicine is and is not designed to do on its own. Getting that context right makes the conversation with a prescriber more productive.

Deciding what to do: the questions worth taking to a prescriber

A plateau is a decision point, not a dead end. The options on the table (continuing at the current dose, discussing a titration step if clinically appropriate, reviewing dietary patterns, or exploring whether a different treatment might suit you better) are not things to navigate from a forum or a search engine. A prescriber who knows your history, your dose timeline and your current weight can tell the difference between a temporary adaptation and a genuine signal to change course.

It is also worth looking at the wider Wegovy treatment picture to understand what the full titration schedule involves and what outcomes the clinical evidence supports. If you have stopped losing weight on Wegovy, understanding whether that reflects a true plateau or something more specific to your situation is an important first step before drawing any conclusions. If you stopped Wegovy at any point before resuming, the dynamics of what happens after a break are worth understanding before drawing conclusions about whether the medicine is still working. And if the concern is that the medicine has simply lost effectiveness over time, the question of Wegovy appearing to stop working has its own clinical nuance that a prescriber is best placed to address.

At nume, a real prescriber reviews your situation, not an automated system. If you want a clinical conversation about where your treatment stands, speaking to our prescribers is a straightforward next step. Your consultation is free, and your first order (if you are clinically suitable) arrives the next working day via DPD, in plain, unbranded packaging, tracked to your door.